Pharmaceuticals News 6 November 2025 - 14 November 2025

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened and what comes next. By Staff Reporter — November 14, 2025 NEW YORK — Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) were under heavy pressure on Friday after the European Medicines Agency’s human medicines committee signaled it is leaning against approving the company’s experimental Alzheimer’s pill blarcamesine for early Alzheimer’s disease. Investing News Network (INN)+1 The Committee for Medicinal

As Wall Street heads into Friday’s session, Pfizer stock is trading slightly lower in premarket action while investors digest a trio of big developments: the completed acquisition of obesity‑drug developer Metsera, a sharp reduction in Pfizer’s stake in BioNTech, and a recent earnings report that lifted 2025 profit guidance but confirmed that COVID revenue continues to fade.Pfizer+2BioSpace+2 Benzinga’s real‑time quote shows Pfizer (NYSE: PFE) around $25.6 ahead of the U.S. market open, roughly 1% belowThursday’s close of $25.79, putting the shares on track for a mildly negative start to the day.Benzinga+1 Below is what traders and long‑term investors should know before the opening bell.

Mangoceuticals, Inc. (NASDAQ: MGRX), the tiny telehealth company best known for its MangoRx men’s wellness brand, is suddenly at the center of the red‑hot obesity drugs market after unveiling a partnership with Eli Lilly and Novo Nordisk to offer official access to their blockbuster GLP‑1 weight‑loss medications Zepbound and Wegovy.GlobeNewswire+1 What Mangoceuticals announced today In a press release and accompanying SEC Form 8‑K filed Thursday, Mangoceuticals said it has launched two integrated programs — MangoRx Direct and PeachesRx Direct — built around official access to GLP‑1 obesity drugs from Eli Lilly and Novo Nordisk.GlobeNewswire+2SEC+2 Under the new model: Mango is

Merck & Co., Inc. (NYSE: MRK) extended this week’s rally on Wednesday as investors digested fresh late‑stage results for its investigational oral PCSK9 inhibitor and an FDA clearance that supports broader precision use of Keytruda-based therapy. Below is what changed today and how it fits into Merck’s 2025 storyline. Today’s highlights at a glance Market move: why MRK is in focus today Merck shares traded higher on Wednesday after back‑to‑back catalysts in cardiometabolic and oncology. The stock’s strength follows AHA 2025 presentations showing that enlicitide—a once‑daily oral PCSK9 inhibitor—cut LDL‑C by 55.8% at 24 weeks vs. placebo in broad hypercholesterolemia

Published: November 11, 2025 Moderna, Inc. (NASDAQ: MRNA) drew multiple analyst headlines today as Wall Street recalibrated views in the wake of last week’s earnings and ongoing cost‑cutting. UBS highlighted potential 2026 upside on pipeline and expense discipline; Redburn Atlantic trimmed its price target; and Bernstein reiterated a neutral stance. Shares traded higher during the U.S. session alongside the commentary. MarketScreener+2MarketScreener+2 Today’s key headlines Stock move: By mid‑session, MRNA traded notably higher—around the mid‑single digits—amid the day’s analyst chatter. Investing.com Why these calls matter Investors are still digesting Q3 2025 results from November 6, when Moderna posted a narrower‑than‑expected loss

GSK plc (NYSE: GSK; LSE: GSK) generated several headlines today: a fresh research tie‑up in tuberculosis drug discovery, confirmation of ongoing share repurchases via a new U.K. regulatory filing, and a U.S.‑listed share price that pushed to a new 12‑month high intraday. BioSpace+2 1) New research collaboration targets TB AN2 Therapeutics announced a collaboration with GSK to advance boron‑based leucyl‑tRNA synthetase (LeuRS) inhibitors for tuberculosis. The effort is supported by a third year of Gates Foundation funding and builds on prior work between AN2 scientists and GSK’s Global Health R&D team, according to the release. Thomas Breuer, GSK’s Chief Global

Summary: Novo Nordisk’s U.S.-listed shares (NYSE: NVO) traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift volumes over time. Investors are also watching a court decision that favored Novo in its bid for obesity biotech Metsera and closely reading this week’s Q3 update and guidance cut. Investopedia+3Reuters+3Novo Nordisk+3 At a Glance — What’s moving NVO on Nov 7, 2025 Market Action Today (Nov 7) By late morning U.S. time, NVO changed hands near $45.42, down ~2.3%

Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC (12:51 p.m. ET), NVO traded around $47.30, down ~2.4% on the day (intraday range: $46.91–$49.49; volume ~29.3M). The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire What’s moving NVO today White House deal cuts